Ipsen SA

Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication

24 4 2025 01:14:23 提供 Nasdaq GlobeNewswire

Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance

15 4 2025 23:57:00 提供 Nasdaq GlobeNewswire

Ipsen - March 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

14 4 2025 11:00:00 提供 Nasdaq GlobeNewswire

Ipsen publishes its 2024 Universal Registration Document

08 4 2025 11:00:00 提供 Nasdaq GlobeNewswire

Ipsen announces issuance of €500 million inaugural Rated Public Bond

19 3 2025 01:00:00 提供 Nasdaq GlobeNewswire

Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins

12 3 2025 01:28:00 提供 Nasdaq GlobeNewswire

Ipsen - February 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

06 3 2025 11:00:00 提供 Nasdaq GlobeNewswire

Ipsen S.A. publishes its 2024 consolidated financial statements

21 2 2025 08:42:27 提供 Nasdaq GlobeNewswire

Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025

12 2 2025 23:57:00 提供 Nasdaq GlobeNewswire

Ipsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

06 2 2025 11:00:00 提供 Nasdaq GlobeNewswire

Ipsen - December 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

07 1 2025 11:00:00 提供 Nasdaq GlobeNewswire

Ipsen - Half year statement - 2024 12 31

07 1 2025 11:00:00 提供 Nasdaq GlobeNewswire

Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

09 12 2024 11:00:00 提供 Nasdaq GlobeNewswire

Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

03 12 2024 00:00:00 提供 Nasdaq GlobeNewswire

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

15 11 2024 10:00:00 提供 Nasdaq GlobeNewswire

Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

07 11 2024 11:00:00 提供 Nasdaq GlobeNewswire

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

23 10 2024 00:00:00 提供 Nasdaq GlobeNewswire

Ipsen receives its second Shingo Prize for operational excellence

14 10 2024 11:00:00 提供 Nasdaq GlobeNewswire

Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

09 10 2024 11:00:00 提供 Nasdaq GlobeNewswire

Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease

23 9 2024 06:13:10 提供 Nasdaq GlobeNewswire